IRIS
CRISCITIELLO, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 669
EU - Europa 155
SA - Sud America 136
NA - Nord America 130
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.126
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 209
CN - Cina 153
VN - Vietnam 98
BR - Brasile 92
US - Stati Uniti d'America 92
IN - India 44
FR - Francia 33
BD - Bangladesh 29
IT - Italia 22
GB - Regno Unito 19
IQ - Iraq 19
AR - Argentina 18
MX - Messico 17
HK - Hong Kong 16
SA - Arabia Saudita 16
TR - Turchia 15
DE - Germania 14
ES - Italia 11
PL - Polonia 11
PK - Pakistan 10
DZ - Algeria 9
ID - Indonesia 9
PH - Filippine 8
MY - Malesia 7
RU - Federazione Russa 7
UA - Ucraina 7
CL - Cile 6
EC - Ecuador 6
MA - Marocco 6
PT - Portogallo 6
ZA - Sudafrica 6
CO - Colombia 5
EG - Egitto 5
CA - Canada 4
DO - Repubblica Dominicana 4
TH - Thailandia 4
TW - Taiwan 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
FI - Finlandia 3
GT - Guatemala 3
JO - Giordania 3
JP - Giappone 3
NL - Olanda 3
PE - Perù 3
SE - Svezia 3
SN - Senegal 3
UZ - Uzbekistan 3
ET - Etiopia 2
GR - Grecia 2
IL - Israele 2
KW - Kuwait 2
NP - Nepal 2
PA - Panama 2
PR - Porto Rico 2
RO - Romania 2
SV - El Salvador 2
AL - Albania 1
AT - Austria 1
BE - Belgio 1
BG - Bulgaria 1
BT - Bhutan 1
CD - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
HU - Ungheria 1
IE - Irlanda 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MN - Mongolia 1
MQ - Martinica 1
MW - Malawi 1
MZ - Mozambico 1
NI - Nicaragua 1
OM - Oman 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 1.126
Salva come PNG Salva come JPEG
Città #
Singapore 56
Beijing 34
Ho Chi Minh City 32
San Jose 19
Hanoi 18
Hong Kong 14
Assago 10
Orem 9
São Paulo 9
Da Nang 8
Frankfurt am Main 7
Hillsboro 7
Santa Clara 7
Riyadh 6
Baghdad 5
Istanbul 5
Jeddah 5
London 5
Madrid 5
New Delhi 5
Rio de Janeiro 5
Warsaw 5
Chennai 4
Dammam 4
Dhaka 4
Kuala Lumpur 4
Mexico City 4
New York 4
Paris 4
Quito 4
Santiago 4
Ashburn 3
Baku 3
Bangkok 3
Barnet 3
Batna City 3
Belo Horizonte 3
Bexley 3
Bogotá 3
Cairo 3
Casablanca 3
Dakar 3
Durban 3
Hyderabad 3
Lahore 3
Los Angeles 3
Phú Thọ 3
Rome 3
Tashkent 3
Wroclaw 3
Addis Ababa 2
Amman 2
Amsterdam 2
Assis 2
Buffalo 2
Can Tho 2
Chandigarh 2
City of London 2
Concepción 2
Congonhas 2
Dnipro 2
Faisalabad 2
Fortaleza 2
Guatemala City 2
Haiphong 2
Helsinki 2
Huế 2
Hải Dương 2
Jakarta 2
Jaraguá do Sul 2
Kaohsiung 2
Karachi 2
Kuwait City 2
Lima 2
Limburg an der Lahn 2
Lisbon 2
Lviv 2
Manchester 2
Manila 2
Marseille 2
Mumbai 2
Najaf 2
Nha Trang 2
Ninh Bình 2
Palma 2
Passo Fundo 2
Quận Hai 2
Rangpur City 2
Rishon LeTsiyyon 2
Santo Domingo 2
Shaoxing 2
Stockholm 2
Surat 2
Thái Nguyên 2
Tokyo 2
Tân Tiến 2
Volta Redonda 2
Abidjan 1
Acalanes Ridge 1
Al Hillah 1
Totale 466
Salva come PNG Salva come JPEG
Nome #
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 21
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer 15
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey 15
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer 14
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 12
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 12
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine 12
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 12
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow 12
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer 12
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 12
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 11
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 11
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 11
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics 11
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials 11
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care 11
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 11
Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021 10
A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report 10
Antibody–drug conjugates in solid tumors: a look into novel targets 10
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 10
PARP Inhibitors for Breast Cancer Treatment 10
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer 9
Evolution of low HER2 expression between early and advanced-stage breast cancer 9
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 9
Best management of locally advanced inoperable breast cancer 9
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 9
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer 9
RNAi screens identify CHD4 as an essential gene in breast cancer growth 9
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 9
Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial 9
Tumori maligni del colon 9
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 9
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 8
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 8
Expression of tumor-associated antigens in breast cancer subtypes 8
HER2-positive circulating tumor cells in breast cancer 8
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence 8
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 8
Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy 8
The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario? 8
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 8
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art 8
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment 8
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection 8
Editorial : Diagnosis and Treatment of Breast Cancer in 2022 : The Rise of Novel Molecular Biomarkers 8
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review 8
[Exemestane in the treatment of breast carcinoma: recent findings] 8
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 8
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 8
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer 8
Neoadjuvant model for testing emerging targeted therapies in breast cancer 8
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 8
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy 8
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing 8
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 7
Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers 7
Tumor-associated antigens in breast cancer 7
Targeting fibroblast growth factor receptor pathway in breast cancer 7
Immunotherapy of Breast Cancer 7
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 7
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability 7
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 7
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management 7
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial 7
Successes and limitations of targeted cancer therapy in breast cancer 7
Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling 7
HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence 7
Understanding the biology of triple-negative breast cancer 7
Locoregional recurrence in patients with HER2 positive breast cancer 7
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy 7
HER2-Low Breast Cancer: a New Subtype? 7
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes 7
No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis 7
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 7
Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer 7
Dendritic cell-based vaccines : clinical applications in breast cancer 7
Peptide vaccines in early breast cancer 7
Immune checkpoint inhibitors with radiotherapy and locoregional treatment : synergism and potential clinical implications 7
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation 7
Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? 7
Characterization of low HER2 expressions in de-novo metastatic breast cancer 7
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 7
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? 7
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 7
Variant allele frequency: a decision-making tool in precision oncology? 7
Incidental thyroid papillary microcarcinoma on 1777 surgically treated patients for benign thyroid disease: A monoinstitutional experience and literature review 6
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting 6
Targeting the subtypes of breast cancer: Rethinking investigational drugs 6
Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours 6
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 6
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion 6
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer 6
Optimal adjuvant chemotherapy in breast cancer : selection of agents 6
Mechanism of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist 6
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 6
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy 6
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact 6
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment 6
Totale 846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.111
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.111
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/20261.325 0 0 0 0 0 0 0 797 337 191 0 0
Totale 1.325